"Telomerase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An essential ribonucleoprotein reverse transcriptase that adds telomeric DNA to the ends of eukaryotic CHROMOSOMES.
| Descriptor ID |
D019098
|
| MeSH Number(s) |
D08.811.913.696.445.308.300.750.750 D12.776.157.687.613 D12.776.157.725.500.921 D12.776.660.720.613 D12.776.664.962.500.921
|
| Concept/Terms |
Telomerase- Telomerase
- Telomerase Reverse Transcriptase
- Reverse Transcriptase, Telomerase
- Transcriptase, Telomerase Reverse
Telomerase Catalytic Subunit- Telomerase Catalytic Subunit
- Catalytic Subunit, Telomerase
- Subunit, Telomerase Catalytic
- Telomerase Reverse Transcriptase Catalytic Subunit
|
Below are MeSH descriptors whose meaning is more general than "Telomerase".
Below are MeSH descriptors whose meaning is more specific than "Telomerase".
This graph shows the total number of publications written about "Telomerase" by people in this website by year, and whether "Telomerase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 |
| 1997 | 3 | 1 | 4 |
| 1999 | 2 | 0 | 2 |
| 2001 | 4 | 0 | 4 |
| 2002 | 0 | 2 | 2 |
| 2003 | 2 | 1 | 3 |
| 2004 | 2 | 3 | 5 |
| 2005 | 0 | 2 | 2 |
| 2006 | 2 | 2 | 4 |
| 2007 | 2 | 0 | 2 |
| 2009 | 0 | 2 | 2 |
| 2010 | 4 | 2 | 6 |
| 2011 | 4 | 5 | 9 |
| 2012 | 2 | 3 | 5 |
| 2013 | 4 | 3 | 7 |
| 2014 | 4 | 9 | 13 |
| 2015 | 4 | 3 | 7 |
| 2016 | 3 | 4 | 7 |
| 2017 | 5 | 2 | 7 |
| 2018 | 4 | 0 | 4 |
| 2019 | 3 | 5 | 8 |
| 2020 | 2 | 4 | 6 |
| 2021 | 1 | 3 | 4 |
| 2022 | 3 | 0 | 3 |
| 2023 | 2 | 0 | 2 |
| 2024 | 1 | 2 | 3 |
| 2025 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Telomerase" by people in Profiles.
-
The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysis. Lancet Oncol. 2025 Sep; 26(9):1178-1190.
-
Telomere attrition becomes an instrument for clonal selection in aging hematopoiesis and leukemogenesis. Nat Genet. 2025 Sep; 57(9):2215-2225.
-
Molecular and clinical determinants of response to checkpoint inhibitor immunotherapy in glioblastoma. J Neurooncol. 2025 Oct; 175(1):453-461.
-
TERT promoter mutations and survival outcomes in adult-type granulosa cell tumors. Int J Gynecol Cancer. 2025 Aug; 35(8):101862.
-
Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles. Nat Commun. 2025 Mar 17; 16(1):2632.
-
Clonal landscape and clinical outcomes of telomere biology disorders: somatic rescue and cancer mutations. Blood. 2024 Dec 05; 144(23):2402-2416.
-
Analytical Validation of a Telomerase Reverse Transcriptase (TERT) Promoter Mutation Assay. J Clin Endocrinol Metab. 2024 Aug 13; 109(9):2269-2273.
-
The DNA methylome of pediatric brain tumors appears shaped by structural variation and predicts survival. Nat Commun. 2024 Aug 08; 15(1):6775.
-
TERT activation targets DNA methylation and multiple aging hallmarks. Cell. 2024 Jul 25; 187(15):4030-4042.e13.
-
Determinants of mosaic chromosomal alteration fitness. Nat Commun. 2024 May 07; 15(1):3800.